TOVX
TOVX
AMEX · Biotechnology

Theriva Biologics Inc

$0.18
-0.02 (-8.95%)
Financial Highlights (FY 2025)
Revenue
1.03M
Net Income
-22,361
Gross Margin
44.9%
Profit Margin
-2.2%
Rev Growth
+0.6%
D/E Ratio
0.84
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 44.9% 44.9% 44.9%
Operating Margin -2.8% -2.6% -2.8%
Profit Margin -2.2% -2.9% -2.6%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 1.03M 1.08M 955.9K
Gross Profit 464.4K 485.2K 429.3K
Operating Income -29,054 -28,405 -26,891
Net Income -22,361 -31,787 -25,174
Gross Margin 44.9% 44.9% 44.9%
Operating Margin -2.8% -2.6% -2.8%
Profit Margin -2.2% -2.9% -2.6%
Rev Growth +0.6% -3.8% +4.7%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 2.39M 2.56M 2.46M
Total Equity 2.86M 2.77M 2.86M
D/E Ratio 0.84 0.93 0.86
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -38,355 -35,389 -33,870
Free Cash Flow -18,843 -19,077 -22,857